“Caelus Health, EnteroBiotix, Ferring Pharmaceuticals, and MaaT Pharma, in coordination with the Pharmabiotic Research Institute…
nboutaouiMay 21, 2019
Independent Data Safety Monitoring Board (DSMB) recommends to continue HERACLES study without modification. Lyon, France,…
nboutaouiFebruary 5, 2019
Data show achievement of primary endpoint, demonstration of functional microbiota restoration, inflammation reduction and positive…
nboutaouiDecember 2, 2018
Lyon, France, November 2, 2018 – MaaT Pharma announced today that the company will present…
MaaT PharmaNovember 6, 2018
Microbiome restoration biological drug product to be tested for safety and overall survival impact in…
MaaT PharmaOctober 12, 2018
Results from in silico analysis using MaaT Pharma’s data analysis platform, GutPrint, demonstrate therapeutic rationale…
MaaT PharmaSeptember 18, 2018
MaaT Pharma receives world-wide exclusive license to technology co-developed with hematology and gastroenterology departments of…
MaaT PharmaJune 21, 2018
MaaT Pharma, a clinical-stage biopharmaceutical company, received authorization from competent authorities to launch its phase…
MaaT PharmaMarch 5, 2018